Aurobindo Pharma peers

·Pharma & HealthChart ›

Companies like Aurobindo Pharmalatest year

Aurobindo PharmaAUROPHARMA · FY26 · this company
Market cap₹95,530
P/E27.26×
Sales growth+16.3%
ROE9.9%
Sun Pharmaceutical IndustriesSUNPHARMA · FY26
Open ›
Market cap₹4,21,677
P/E36.77×
Sales growth+10.5%
ROE14.7%
Dr. Reddy's LaboratoriesDRREDDY · FY26
Open ›
Market cap₹1,11,506
P/E26.49×
Sales growth−1.5%
ROE11.8%
CiplaCIPLA · FY26
Open ›
Market cap₹1,10,313
P/E28.43×
Sales growth−2.4%
ROE11.8%

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AUROPHARMA₹1,644.80

Aurobindo Pharma Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMADRREDDYCIPLAFORTISLUPINALKEMLAURUSLABSMANKINDMcap ₹95,530 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
AUROPHARMA
FY26
SUNPHARMA
FY26
DRREDDY
FY26
CIPLA
FY26
Peer
Average
Valuation — at last close
P/E27.26×36.77×◆ 26.49×28.43×30.56× -11%
P/B◆ 2.52×5.05×2.94×3.20×3.73× -32%
EV/EBITDA◆ 13.52×22.19×17.19×17.28×18.89× -28%
Market Cap₹95,530 Cr₹4.22L Cr₹1.12L Cr₹1.10L Cr₹2.14L Cr -55%
Growth
Revenue CAGR 3Y10.63%10.03%◆ 10.96%7.37%9.45% +12%
Revenue CAGR 5Y6.32%11.78%◆ 12.09%8.01%10.63% -41%
Net Income CAGR 3Y◆ 22.03%10.57%-2.66%10.88%6.26% +252%
Revenue YoY (latest Q)◆ 16.30%10.46%-1.48%-2.44%2.18% +648%
Net Income YoY (latest Q)25.22%◆ 26.53%-31.69%-37.08%-14.08% +279%
Profitability
EBITDA Margin20.34%◆ 30.33%19.15%20.89%23.46% -13%
Net Income Margin10.41%◆ 19.69%12.34%13.71%15.25% -32%
Return on Common Equity9.94%◆ 14.74%11.75%11.82%12.77% -22%
Return on Capital Employed13.41%◆ 18.48%11.30%13.87%14.55% -8%
Return on Assets6.47%◆ 11.46%7.73%9.67%9.62% -33%
Credit & Quality
Total Debt/Equity0.20×0.05×0.16×◆ 0.01×0.07× +173%
Interest Coverage13.20×43.65×11.76×◆ 85.90×47.10× -72%
Scale — latest FY
Revenue / Total Income₹33,653 Cr₹58,462 Cr₹33,700 Cr₹28,163 Cr₹40,108 Cr -16%
Net Income₹3,503 Cr₹11,509 Cr₹4,158 Cr₹3,862 Cr₹6,509 Cr -46%
Total Assets₹58,502 Cr₹1.09L Cr₹58,123 Cr₹42,496 Cr₹69,802 Cr -16%
EPS₹60.34₹47.8₹50.41₹48.03₹48.75 +24%
Book Value per Share₹652.39₹348.31₹453.79₹426.24₹409.45 +59%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.